GATA1 and acute myeloid leukemia: The TAM Prevention 2007 (TMD07) trial aimed to reduce the incidence of AML in children diagnosed with TAM by applying a low-dose cytarabine treatment in combination with minimal residual disease (MRD) monitoring to eradicate the GATA1-mutated clone [23].